Journal of Controlled Release最新文献

{"title":"Welcoming Prof. Paolo Caliceti as Deputy Editor-in-Chief","authors":"Yu-Kyoung Oh , Yoon Yeo , Stefaan C. De Smedt","doi":"10.1016/j.jconrel.2025.01.052","DOIUrl":"10.1016/j.jconrel.2025.01.052","url":null,"abstract":"","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"379 ","pages":"Page 848"},"PeriodicalIF":10.5,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143039020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing innovative drug delivery technologies for women's health","authors":"Hagar I. Labouta , S. Rahima Benhabbour","doi":"10.1016/j.jconrel.2025.01.067","DOIUrl":"10.1016/j.jconrel.2025.01.067","url":null,"abstract":"","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"379 ","pages":"Page 849"},"PeriodicalIF":10.5,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Engineering biocompatible carbon dots nano-enzymes hydrogel for efficient antioxidative and anti-inflammatory treatment of dry eye disease.","authors":"Hailing Yu, Xinxi Yu, Yin Huang, Ting Yu, Huimin Lan, Qianqian Zhang, Yongquan Huang, Xin Peng, Zebo Jiang","doi":"10.1016/j.jconrel.2025.01.081","DOIUrl":"https://doi.org/10.1016/j.jconrel.2025.01.081","url":null,"abstract":"<p><p>Dry eye disease (DED) is a complex and multifactorial ocular surface disease. Reactive oxygen species (ROS) are of pivotal importance in the inflammatory processes and biological dysfunction associated with DED. In this study, an injectable hydrogel, designated as OHACDgel, was created by combining oxidized HA-containing aldehyde groups (OHA) and gelation (gel) via dynamic covalent linkages of the hydrazine bonds, is employed as the carrier, while polyethylene imine-functionalized carbon dots (PEI-CD) can form dynamic chemical bonds with the hydrogel, thus prolonging the retention time of the ocular. OHACDgel has been demonstrated to markedly diminish ROS overproduction, reduce the expression of pro-inflammatory factors, inhibit the transformation of macrophages into a pro-inflammatory phenotype, reverse corneal epithelial defects, restore goblet cell function, and enhance tear secretion. Furthermore, the biocompatibility of OHACDgel has been demonstrated, presenting a rapid and straightforward therapeutic option for potential applications in DED.</p>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":" ","pages":""},"PeriodicalIF":10.5,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-assembled HO-1i-Pt(IV) nanomedicine targeting p38/MAPK and MDR pathways for cancer chemo-immunotherapy","authors":"Xiao-Meng Liu ,&nbsp;Zhe Li ,&nbsp;Xiao-Ya Wang ,&nbsp;Bo-Wen Ding ,&nbsp;Jia-Qian Wang ,&nbsp;Xin Qiao ,&nbsp;Yu-Kuan Feng ,&nbsp;Ji-Hui Hao ,&nbsp;Jing-Yuan Xu","doi":"10.1016/j.jconrel.2025.01.050","DOIUrl":"10.1016/j.jconrel.2025.01.050","url":null,"abstract":"<div><div>Platinum(II)-based antitumor drugs are widely used in clinics but limited by severe side effects and resistance. Multi-target Platinum(IV) complexes are emerging as ideal alternatives. Heme oxygenase-1 (HO-1) works as a rate-limiting step in heme degradation and is overexpressed in malignant tumors. Herein, HO-1i-based Platinum(IV) prodrugs are prepared and candidate complex <strong>15</strong> is further developed into self-assembled nanoparticles (<strong>15</strong>-NPs). <strong>15</strong> and <strong>15</strong>-NPs significantly increase cytotoxicity, particularly in HepG2 (74.77- and 96.14-fold increases) and A549cisR (38.6- and 47.24-fold increases), while reducing toxicity towards normal cells compared to cisplatin. <em>In vitro</em> experiments show <strong>15</strong> and <strong>15</strong>-NPs activated multiple pathways, including p38/MAPK- and MDR-related proteins, achieving multi-target synergistic chemosensitization and anti-resistance, further verified by RNA-sequencing analysis. <em>In vivo</em> tests demonstrate that <strong>15</strong> and <strong>15</strong>-NPs efficiently inhibit tumor growth and systemic toxicity, especially <strong>15</strong>-NPs with optimal tumor-inhibition rate and survival (80% and 100%), superior to cisplatin (40% and 50%), attributing to its extra endocytosis, EPR effect, and precisely tumor-targeted release besides the advantage of a free HO-1i-Pt(IV) prodrug. Additionally, <strong>15</strong> and <strong>15</strong>-NPs distinctly regulate T-cell and macrophage functions, thereby exhibiting a chemoimmuno-combined action. This study highlights that multi-functional Platinum(IV) prodrug target-delivered to tumors <em>via</em> carrier-free nanoparticles may represent an effective modality for improving cancer therapy.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"379 ","pages":"Pages 797-813"},"PeriodicalIF":10.5,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disrupting the dangerous alliance: Dual anti-inflammatory and anticoagulant strategy targets platelet-neutrophil crosstalk in sepsis","authors":"Sa Chen,&nbsp;Aijia Wu,&nbsp;Xinran Shen,&nbsp;Jinxia Kong,&nbsp;Yuan Huang","doi":"10.1016/j.jconrel.2025.01.053","DOIUrl":"10.1016/j.jconrel.2025.01.053","url":null,"abstract":"<div><div>Sepsis is a life-threatening disease characterized by excessive systemic inflammation and coagulopathy. Platelets and neutrophils form a “dangerous alliance” through crosstalk, promoting the inflammatory cytokine storm and coagulation disorders during sepsis. Platelet-neutrophil crosstalk leads to the formation of platelet-neutrophil complexes (PNCs), which are the central “protagonists” of this “dangerous alliance.” These PNCs further enhance the crosstalk between platelets and neutrophils, amplifying immune and coagulation responses through positive feedback loops. Although some targeted therapies have been reported recently, they primarily focus on inducing neutrophil apoptosis or degrading existing neutrophil extracellular traps (NETs). Limited strategies are available for targeting platelets and suppressing sepsis-associated PNCs. Herein, we propose a two-pronged approach to intercept platelet-neutrophil crosstalk by simultaneously targeting drugs to both platelets and neutrophils of the “dangerous alliance.” This strategy not only effectively alleviates inflammation induced by platelet-neutrophil crosstalk but also reduces PNC formation, thereby dismantling the structural scaffold of microthrombi. In a sepsis mouse model, this approach significantly decreased markers of platelet-neutrophil crosstalk, reduced the cytokine storm, and lowered the risk of thrombosis. Moreover, it alleviated organ damage caused by PNC infiltration and prolonged the survival of septic mice. Overall, this work combines anti-inflammatory and anticoagulant therapies to effectively disrupt the “dangerous alliance” between platelets and neutrophils, offering a promising strategy for treating sepsis.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"379 ","pages":"Pages 814-831"},"PeriodicalIF":10.5,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smart core-shell microneedles for psoriasis therapy: In situ self-assembly of calcium ion-coordinated dexamethasone hydrogel","authors":"Xinni He ,&nbsp;Wanchen Zhao ,&nbsp;Huihui Xu ,&nbsp;Hongluo Li ,&nbsp;Minglong Chen ,&nbsp;Yanping Fu ,&nbsp;Shujin Liang ,&nbsp;Shuling Li ,&nbsp;Tingting Peng ,&nbsp;Chao Lu ,&nbsp;Xin Pan ,&nbsp;Chuanbin Wu ,&nbsp;Guilan Quan","doi":"10.1016/j.jconrel.2025.01.037","DOIUrl":"10.1016/j.jconrel.2025.01.037","url":null,"abstract":"<div><div>Psoriasis is a prevalent relapsing dermatological condition that often necessitates lifelong treatment. The distinctive thickening of the <em>stratum corneum</em> presents a challenge to drug penetration. The employment of microneedles has been demonstrated to enhance the transdermal drug delivery efficacy by creating multiple microchannels in the skin. Nevertheless, polymeric microneedles often encounter difficulties in meeting the requirements for sustained drug release. It is imperative to acknowledge that sustained-release hydrogel microneedles are invariably fabricated under harsh crosslinking conditions. In addressing these challenges, a core-shell microneedles (CSMNs) system was customized at a facile, accessible process, enabling the <em>in situ</em> formation of supramolecular microhydrogels within the skin. This concept was realized by leveraging the interaction between the therapeutic drug dexamethasone sodium phosphate (DexP) and calcium chloride (CaCl₂), combined with the differential biphasic release technology (DexP HMNs). Upon insertion into the skin, the core of the microneedles rapidly released CaCl₂, which diffused to the shell and formed a hydrogel with DexP, creating multiple reservoirs for the sustained release of DexP. <em>In vitro</em> transdermal permeation experiments demonstrated that DexP HMNs greatly prolonged the skin retention time of DexP. In the context of psoriasis treatment, DexP HMNs were demonstrated to be more effective than DexP CSMNs in inhibiting keratinocyte proliferation and significantly reducing the levels of inflammatory factors and immune cell infiltration at the lesion site. This study provides a new direction for the development of intelligent microneedle drug delivery systems for sustained drug release and enhanced management of chronic skin diseases.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"379 ","pages":"Pages 786-796"},"PeriodicalIF":10.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142991712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing the Potential of Human Breast Milk to Boost Intestinal Permeability for Nanoparticles and Macromolecules","authors":"Si Naftaly ,&nbsp;Topaz Pery ,&nbsp;Rawan Mhajne ,&nbsp;Areen Ashkar ,&nbsp;Maya Davidovich-Pinhas ,&nbsp;Assaf Zinger","doi":"10.1016/j.jconrel.2025.01.049","DOIUrl":"10.1016/j.jconrel.2025.01.049","url":null,"abstract":"<div><div>The intricate interplay between human breast milk, nanoparticles, and macromolecules holds promise for innovative nutritional delivery strategies. Compared to bovine milk and infant formula, this study explores human breast milk's role in modulating intestinal permeability and its impact on nanoparticle and macromolecule transport. Comparative analysis with bovine milk and infant formula reveals significant elevations in permeability with human breast milk, accompanied by a decrease in transepithelial electrical resistance, suggesting enhanced paracellular transport. Mechanistically, human breast milk reduces Zonula occludens-1 levels, suggesting a regulatory role in intestinal barrier function. Through <em>in vitro</em> and <em>ex vivo</em> evaluations, we aim to understand better the mechanisms behind enhanced permeability and how human breast milk affects nanoparticle physicochemical properties, potentially modulating their behavior. Specifically, human breast milk improves the intestinal permeability of liposomes in a porcine intestinal model, with associated changes in the composition of milk proteins corona related to liposome charge. These findings underscore the unexploited potential of human breast milk in facilitating transport across the intestinal barrier, offering novel avenues for human nutritional delivery and therapeutic interventions.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"379 ","pages":"Pages 768-785"},"PeriodicalIF":10.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In situ vaccine “seeds” for enhancing cancer immunotherapy by exploiting apoptosis-associated morphological changes","authors":"Binghua Wang ,&nbsp;Rong Guo ,&nbsp;Furui Qiu ,&nbsp;Zhenzhong Zhang ,&nbsp;Xiang Lu ,&nbsp;Hongling Zhang","doi":"10.1016/j.jconrel.2025.01.055","DOIUrl":"10.1016/j.jconrel.2025.01.055","url":null,"abstract":"<div><div>Despite the development of many effective immunoadjuvants (IAs), the therapeutic efficacy of <em>in situ</em> vaccines for anti-tumor applications remains limited. Inspired by the morphological changes occurring during apoptosis, this study aims to leverage the release process of autologous tumor antigens (ATAs) to enhance the anti-tumor activity of <em>in situ</em> vaccines. We developed five distinct liposomes, each with unique characteristics and functions, incorporating FDA-approved monophosphoryl lipid A (MPLA) adjuvants into their lipid bilayers. Our findings revealed that the apoptotic bodies generated from tumor cells treated with membrane-fusion liposomes (MFLs) exhibited a greater capacity for immune activation. Mechanistic studies demonstrated that MFLs can utilize the morphological changes associated with apoptosis to accurately deliver adjuvants to apoptotic bodies. To further optimize the efficiency of antigen presentation by these apoptotic bodies as an adjuvant redistribution platform, we encapsulated a calcium chelator within the MFLs to inhibit the externalization of phosphatidylserine (PS) during apoptosis. Through a series of apoptosis-related cellular events, the vaccine can widely disseminate immunoadjuvants (IAs) within tumor tissues, similar to the dispersal of plant seeds. To the best of our knowledge, this is the first approach to utilize apoptosis-associated morphological changes to enhance the immunotherapeutic efficacy of cancer vaccines.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"379 ","pages":"Pages 757-767"},"PeriodicalIF":10.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143034971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase-separating Pt(IV)-graft-glycopeptides sequentially sensing pH and redox for deep tumor penetration and targeting chemotherapy","authors":"Dali Chen ,&nbsp;Yunai Du ,&nbsp;Xitong Wang ,&nbsp;Huihong Li ,&nbsp;Xinjiao Wu ,&nbsp;Xiaoqin Kuang ,&nbsp;Chunjiayu Li ,&nbsp;Jianing Zhao ,&nbsp;Yerong Xiong ,&nbsp;Minjie Sun ,&nbsp;Jiasheng Tu ,&nbsp;Siyan Liu ,&nbsp;Chunmeng Sun","doi":"10.1016/j.jconrel.2025.01.038","DOIUrl":"10.1016/j.jconrel.2025.01.038","url":null,"abstract":"<div><div>Active-targeting nanomedicines have been widely employed in cancer treatment for increasing therapeutic index. However, the limited permeability caused by the binding site barrier (BSB) and size hindrances compromises their clinical antitumor efficacy in patients. Herein, learning from the liquid-liquid phase separation (LLPS) of bio-macromolecules, we report phase-separating glycopeptides (HEP) from polyhistidine (PHis) grafted hyaluronic acid (HA), which can sense the tumor extracellular pH and concomitantly overcome size and BSB dilemmas for enhanced tumor penetration. HEP aggregates into nanodroplets in solution at neutral pH. Upon reaching the acidic extracellular environment of tumors, the pH-responsive PHis triggers a phase separation, converting the coacervate nanodroplets into monomeric glycopeptides. This enables HEP conjugated with the platinum prodrug (HEPPt) to deeply penetrate into tumors by overcoming the BSB effect arising from the interaction between nanodroplets and cluster of differentiation 44 (CD44), as well as resolving the size challenges. Moreover, HEPPt in monomeric states exhibits promoted cellular uptake after pH-triggered phase separation, attributed to the transmembrane effect of exposed PHis. Subsequently, the rapid release of Pt(II), triggered by tumor intracellular reducing environment, exerts excellent antitumor activity. The phase-separating glycopeptides represent a promising platform for improving tumor penetration and intracellular delivery of therapeutic agents.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"379 ","pages":"Pages 743-756"},"PeriodicalIF":10.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142991654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disclosing long-term tolerance, efficacy and penetration properties of hyaluronic acid-coated latanoprost-loaded liposomes as chronic glaucoma therapy","authors":"Marco Brugnera ,&nbsp;Marta Vicario-de-la-Torre ,&nbsp;Miriam Ana González-Cela-Casamayor ,&nbsp;Felipe M. González-Fernández ,&nbsp;Ilaria Ferraboschi ,&nbsp;Vanessa Andrés-Guerrero ,&nbsp;Sara Nicoli ,&nbsp;Cristina Sissa ,&nbsp;Silvia Pescina ,&nbsp;Rocío Herrero-Vanrell ,&nbsp;Irene Bravo-Osuna","doi":"10.1016/j.jconrel.2025.01.041","DOIUrl":"10.1016/j.jconrel.2025.01.041","url":null,"abstract":"<div><div>Frequent topical administration of hypotensive eye drops in glaucoma patients may lead to the development of dry eye disease (DED) symptoms, because of tear film destabilization and the adverse effects associated with antiglaucoma formulations. To address all this, in the current study preservative-free latanoprost-loaded (0.005 % <em>w/v</em>) synthetic phosphatidylcholine (1,2-dioleoyl-sn-glycero-3-phosphocholine 0.75 % <em>w/v</em>, 1,2-dimyristoyl-sn-glycero-3-phosphocholine 0.25 % <em>w/v</em>) liposomes dispersed in the mucoadhesive polymer hyaluronic acid (0.2 % <em>w/v</em>), containing the osmoprotective ingredients betaine (0.40 % <em>w/v</em>) and leucine (0.90 % <em>w/v</em>) (LAT-HA-LIP), have been prepared and further characterised. Permeation and retention evaluations on a validated <em>ex vivo</em> porcine eye model revealed that the active metabolite latanoprost acid was quantified only starting from LAT-HA-LIP once passing conjunctiva, sclera and choroid compared to the marketed latanoprost (0.005 % <em>w/v</em>) benchmark (MF). The liposomal formulation outperformed MF when applied to the corneal tissue. Additionally, distribution and interactions within corneal and scleral tissues were investigated by means of two-photon microscopy with liposomal formulations containing coumarin-6. Furthermore, acute and chronic tolerance studies on rabbits revealed no signs of discomfort or ocular damage. Schirmer's test, tear osmolarity, tear breakup time (TBUT) and fluorescence staining evaluated through the Oxford grading scale, were assessed as DED diagnostic parameters over a 25-day monitoring period; LAT-HA-LIP consistently maintained levels comparable to physiological solution (0.9 % <em>w/v</em> NaCl) used as control, with a slight increase of TBUT values from day 15 (6.00 ± 0.63 s for control, 7.00 ± 0.78 s for LAT-HA-LIP at day 15, <em>p</em> = 0.0066). A daily topical application of LAT-HA-LIP for 15 consecutive days, effectively lowered IOP in a sustained way (2.51–3.88 mmHg mean IOP reduction over the 5–15-day period). These results highlight the clinical relevance of the proposed technological platform, able to provide IOP reduction during the simulated long-term administration and simultaneous ocular surface protection with potential for the treatment of glaucoma.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"379 ","pages":"Pages 730-742"},"PeriodicalIF":10.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142991652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}